Table 1

Characteristics of study subjects

Discovery cohortValidation cohort
n=127n=77
Age, years54±1757±17
Body mass index, kg/m228±729±8
Female, n (%)89 (70)47 (61)
Caucasian ethnicity, n (%)111 (87)58 (75)
Vasoresponder, n (%)8 (6)
Heritable PAH, n (%)9 (7)2 (3)
Baseline haemodynamics
 Mean pulmonary artery pressure, mm Hg52±1649±12
 Pulmonary artery wedge pressure, mm Hg12±511±5
 Pulmonary vascular resistance, WU11±611±5
 Cardiac output, L/min4.3±1.63.9±1.6
Functional capacity
 6MWD, m313±158263±162
 WHO-FC III/IV, n (%)94 (74)55 (72)
Laboratory investigations
 NT-proBNP, ng/mL711±8391316±1287
 Bilirubin, μmol/L14±1018±9
 Creatinine, mg/dL86±3199±50
 C reactive protein, mg/dL5±79±12
Medication
 Phosphodiesterase type 5 inhibitor, n (%)97 (76)42 (54)
 Endothelin receptor antagonist, n (%)51 (40)47 (61)
 Prostacyclin analogue, n (%)23 (18)8 (10)
 Statin, n (%)38 (30)21 (27)
 Oral anticoagulation, n (%)100 (79)51 (66)
 ACE inhibitor, n (%)19 (15)23 (30)
 Diuretics, n (%)58 (46)48 (62)
 Aldosterone antagonists, n (%)47 (37)33 (43)
Comorbidities
 Atrial fibrillation/flutter, n (%)21 (17)16 (21)
 Diabetes mellitus, n (%)24 (19)19 (25)
 Coronary artery disease, n (%)19 (15)21 (27)
 COPD, n (%)10 (8)16 (21)
 Systemic hypertension, n (%)38 (30)25 (33)
  • Means and SDs or counts are given.

  • COPD, chronic obstructive pulmonary disease; 6MWD, 6 min walk distance; NT-proBNP, N-terminal pro-brain natriuretic peptide; WC, Wood units; WHO-FC, WHO functional class.